Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...
This recent safety and effectiveness data regarding mpox vaccination with Jynneos is important and timely given the ongoing ...
Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...
Several Democratic-led states have taken legal action against the Trump administration over its decision to retract $11 ...
Jynneos was the first smallpox vaccine developed under Project BioShield, a program created by Congress in 2004 to accelerate ...
2d
Pharmaceutical Technology on MSNFDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccineThe formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...
The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...
The US Food and Drug Administration (FDA) has approved the freeze-dried formulation of Bavarian Nordic’s smallpox and mpox vaccine in a move expected to provide flexibility in stockpiling the jab.
March 31 (Reuters) - Denmark's Bavarian Nordic (BAVA.CO), opens new tab said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results